Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

6.770 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.770
Bid (Size) 6.090 (200)
Ask (Size) 6.950 (100)
Prev. Close 6.770
Today's Range 6.770 - 6.770
52wk Range 4.390 - 10.42
Shares Outstanding 37,953,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DiaMedica Therapeutics Inc.
Via Business Wire

Performance

YTD
-14.6%
-14.6%
1 Month
-15.3%
-15.3%
3 Month
+3.7%
+3.7%
6 Month
-10.2%
-10.2%
1 Year
+43.4%
+43.4%

More News

Read More
News headline image
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Death
News headline image
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
RedChip's Biotech Virtual Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Via ACCESS Newswire
News headline image
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗
Via Benzinga
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
From DiaMedica Therapeutics Inc
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
DiaMedica Therapeutics Inc (NASDAQ:DMAC) Reports Q3 2025 Earnings and Clinical Progress ↗
Via Chartmill
News headline image
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire

Frequently Asked Questions

Is DiaMedica Therapeutics Inc. - Common Stock publicly traded?
Yes, DiaMedica Therapeutics Inc. - Common Stock is publicly traded.
What exchange does DiaMedica Therapeutics Inc. - Common Stock trade on?
DiaMedica Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for DiaMedica Therapeutics Inc. - Common Stock?
The ticker symbol for DiaMedica Therapeutics Inc. - Common Stock is DMAC on the Nasdaq Stock Market
What is the current price of DiaMedica Therapeutics Inc. - Common Stock?
The current price of DiaMedica Therapeutics Inc. - Common Stock is 6.770
When was DiaMedica Therapeutics Inc. - Common Stock last traded?
The last trade of DiaMedica Therapeutics Inc. - Common Stock was at 08/06/26 04:00 PM ET
What is the market capitalization of DiaMedica Therapeutics Inc. - Common Stock?
The market capitalization of DiaMedica Therapeutics Inc. - Common Stock is 256.95M
How many shares of DiaMedica Therapeutics Inc. - Common Stock are outstanding?
DiaMedica Therapeutics Inc. - Common Stock has 257M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.